Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Seigo Abiru is active.

Publication


Featured researches published by Seigo Abiru.


Hepatology | 2007

Anti‐gp210 and anti‐centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Minoru Nakamura; Hisayoshi Kondo; Tsuyoshi Mori; Atsumasa Komori; Mutsumi Matsuyama; Masahiro Ito; Yasushi Takii; Makiko Koyabu; Terufumi Yokoyama; Kiyoshi Migita; Manabu Daikoku; Seigo Abiru; Hiroshi Yatsuhashi; Eiichi Takezaki; Naohiko Masaki; Kazuhiro Sugi; Koichi Honda; Hiroshi Adachi; Hidehiro Nishi; Yukio Watanabe; Yoko Nakamura; Masaaki Shimada; Tatsuji Komatsu; Akira Saito; Takeo Saoshiro; Hideharu Harada; Takeshi Sodeyama; Shigeki Hayashi; Akihide Masumoto; Takehiro Sando

The predictive role of antinuclear antibodies (ANAs) remains elusive in the long‐term outcome of primary biliary cirrhosis (PBC). The progression of PBC was evaluated in association with ANAs using stepwise Cox proportional hazard regression and an unconditional stepwise logistic regression model based on the data of 276 biopsy‐proven, definite PBC patients who have been registered to the National Hospital Organization Study Group for Liver Disease in Japan (NHOSLJ). When death of hepatic failure/liver transplantation (LT) was defined as an end‐point, positive anti‐gp210 antibodies (Hazard ratio (HR) = 6.742, 95% confidence interval (CI): 2.408, 18.877), the late stage (Scheuers stage 3, 4) (HR = 4.285, 95% CI:1.682,10.913) and male sex (HR = 3.266, 95% CI: 1.321,8.075) were significant risk factors at the time of initial liver biopsy. When clinical progression to death of hepatic failure/LT (i.e., hepatic failure type progression) or to the development of esophageal varices or hepatocellular carcinoma without developing jaundice (Total bilirubin < 1.5 mg/dL) (i.e., portal hypertension type progression) was defined as an end‐point in the early stage (Scheuers stage 1, 2) PBC patients, positive anti‐gp210 antibodies was a significant risk factor for hepatic failure type progression [odds ratio (OR) = 33.777, 95% CI: 5.930, 636.745], whereas positive anti‐centromere antibodies was a significant risk factor for portal hypertension type progression (OR = 4.202, 95% CI: 1.307, 14.763). Histologically, positive anti‐gp210 antibodies was most significantly associated with more severe interface hepatitis and lobular inflammation, whereas positive anticentromere antibodies was most significantly associated with more severe ductular reaction. Conclusion: These results indicate 2 different progression types in PBC, hepatic failure type and portal hypertension type progression, which may be represented by positive‐anti‐gp210 and positive‐anticentromere antibodies, respectively. (HEPATOLOGY 2007;45:118–127.)


Liver International | 2006

Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis

Seigo Abiru; Kiyoshi Migita; Yumi Maeda; Manabu Daikoku; Masahiro Ito; Kazuyuki Ohata; Shinya Nagaoka; Takehiro Matsumoto; Yasushi Takii; Koichiro Kusumoto; Minoru Nakamura; Atsumasa Komori; Koji Yano; Hiroshi Yatsuhashi; Katsumi Eguchi; Hiromi Ishibashi

Abstract: Background: Although the pathogenesis of non‐alcoholic steatohepatitis (NASH) remains poorly understood, proinflammatory cytokines seem to play an important role in the process of NASH. We have undertaken this study in order to elucidate the role of proinflammatory cytokines and their soluble receptors in NASH patients.


Hepatology | 2014

Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients

Kazumi Yamasaki; Masakuni Tateyama; Seigo Abiru; Atsumasa Komori; Shinya Nagaoka; Akira Saeki; Satoru Hashimoto; Ryu Sasaki; Shigemune Bekki; Yuki Kugiyama; Yuri Miyazoe; Atsushi Kuno; Masaaki Korenaga; Akira Togayachi; Makoto Ocho; Masashi Mizokami; Hisashi Narimatsu; Hiroshi Yatsuhashi

The Wisteria floribunda agglutinin‐positive human Mac‐2‐binding protein (WFA+‐M2BP) was recently shown to be a liver fibrosis glycobiomarker with a unique fibrosis‐related glycoalteration. We evaluated the ability of WFA+‐M2BP to predict the development of hepatocellular carcinoma (HCC) in patients who were infected with the hepatitis C virus (HCV). A total of 707 patients who had been admitted to our hospital with chronic HCV infection without other potential risk factors were evaluated to determine the ability of WFA+‐M2BP to predict the development of HCC; factors evaluated included age, sex, viral load, genotypes, fibrosis stage, aspartate and alanine aminotransferase levels, bilirubin, albumin, platelet count, alpha‐fetoprotein (AFP), WFA+‐M2BP, and the response to interferon (IFN) therapy. Serum WFA+‐M2BP levels were significantly increased according to the progression of liver fibrosis stage (P < 0.001). In each distinctive stage of fibrosis (F0‐F1, F2, F3, and F4), the risk of development of HCC was increased according to the elevation of WFA+‐M2BP. Multivariate analysis identified age >57 years, F4, AFP >20 ng/mL, WFA+‐M2BP ≥4, and WFA+‐M2BP 1‐4 as well as the response to IFN (no therapy vs. sustained virological response) as independent risk factors for the development of HCC. The time‐dependent areas under the receiver operating characteristic curve demonstrated that the WFA+‐M2BP assay predicted the development of HCC with higher diagnostic accuracy than AFP. Conclusion: WFA+‐M2BP can be applied as a useful surrogate marker for the risk of HCC development, in addition to liver biopsy. (Hepatology 2014;60:1563–1570)


Laboratory Investigation | 2005

Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis

Yasushi Takii; Minoru Nakamura; Masahiro Ito; Terufumi Yokoyama; Atsumasa Komori; Yuki Shimizu-Yoshida; Rumiko Nakao; Koichiro Kusumoto; Shinya Nagaoka; Koji Yano; Seigo Abiru; Toshihito Ueki; Takehiro Matsumoto; Manabu Daikoku; Ken Taniguchi; Hikaru Fujioka; Kiyoshi Migita; Hiroshi Yatsuhashi; Masahiro Nakashima; Mine Harada; Hiromi Ishibashi

The pathogenesis of primary biliary cirrhosis (PBC) remains enigmatic. In order to address this issue, we analyzed by laser capture microdissection and real-time reverse transcription-polymerase chain reaction the site-specific expression of messenger RNA (mRNA) for cytokines (interferon (IFN)-α, -β, -γ, interleukin (IL)-1β, -4, -6, -10, -12p40, -18, tumor necrosis factor-α) and toll-like receptors (TLRs) (TLR-2, -3, -4, -7, -9) in portal tract and liver parenchyma from patients with early-stage PBC. Expression of IFN-α, -β and TLR-3 proteins was also studied by immunohistochemistry. Autoimmune hepatitis (AIH) and chronic hepatitis C (CHC) served as disease controls. The expression levels of type I IFN (IFN-α, -β) and TLR-3 mRNAs, which are known to induce type I IFN, were significantly higher in portal tract and liver parenchyma as compared to AIH and CHC. A strong positive correlation between the mRNA levels of type I IFN and TLR-3 was also seen in both areas. Immunohistologically, IFN-α is present in the mononuclear cells in portal tract and sinusoidal cells. Macrophages in portal tract and hepatocytes expressed IFN-β and TLR-3. Furthermore, the level of IFN-α mRNA in the portal tract was positively correlated with serum alkaline phosphatase. In conclusion, these data indicate that TLR-3 and type I IFN signaling pathways are active in both the portal tract and liver parenchyma of early-stage PBC, and form the basis for our hypothesis that these signaling pathways are involved in the pathophysiology of PBC.


PLOS ONE | 2015

Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response

Ryu Sasaki; Kazumi Yamasaki; Seigo Abiru; Atsumasa Komori; Shinya Nagaoka; Akira Saeki; Satoru Hashimoto; Shigemune Bekki; Yuki Kugiyama; Atsushi Kuno; Masaaki Korenaga; Akira Togayachi; Makoto Ocho; Masashi Mizokami; Hisashi Narimatsu; Tatsuki Ichikawa; Kazuhiko Nakao; Hiroshi Yatsuhashi

Measurement of Wisteria floribunda agglutinin-positive human Mac-2 binding protein (WFA+-M2BP) in serum was recently shown to be a noninvasive method to assess liver fibrosis. The aim of this study was to evaluate the utility of serum WFA+-M2BP values to predict the development of hepatocellular carcinoma (HCC) in patients who achieved a sustained virological response (SVR) by interferon treatment. For this purpose, we retrospectively analyzed 238 patients with SVR who were treated with interferon in our department. Serum WFA+-M2BP values were measured at pre-treatment (pre-Tx), post-treatment (24 weeks after completion of interferon; post-Tx), the time of HCC diagnosis, and the last clinical visit. Of 238 patients with SVR, HCC developed in 16 (6.8%) patients. The average follow-up period was 9.1 years. The cumulative incidence of HCC was 3.4% at 5 years and 7.5% at 10 years. The median pre-Tx and post-Tx WFA+-M2BP values were 1.69 (range: 0.28 to 12.04 cutoff index (COI)) and 0.80 (range: 0.17 to 5.29 COI), respectively. The WFA+-M2BP values decreased significantly after SVR (P < 0.001). The median post-Tx WFA+-M2BP value in patients who developed HCC was significantly higher than that in patients who did not (P < 0.01). Multivariate analysis disclosed that age (> 60 years), sex (male), pre-Tx platelet count (< 15.0×103/μL), and post-Tx WFA+-M2BP (> 2.0 COI) were associated with the development of HCC after SVR. Conclusion Post-Tx WFA+-M2BP (> 2.0 COI) is associated with the risk for development of HCC among patients with SVR. The WFA+-M2BP values could be a new predictor for HCC after SVR.


Intervirology | 2010

Dynamic Epidemiology of Acute Viral Hepatitis in Japan

Koji Yano; Yoko Tamada; Hiroshi Yatsuhashi; Atsumasa Komori; Seigo Abiru; Kiyoaki Ito; Naohiko Masaki; Masashi Mizokami; Hiromi Ishibashi

The epidemiology of acute viral hepatitis (AVH) is dynamic and affected by many factors including hygiene, socioeconomic status and vaccination coverage. A total of 4,302 cases of AVH were sequentially enrolled in this nationwide study between 1980 and 2008. Of the cases of AVH, acute hepatitis A (AHA) accounted for 1,583 (36.8%), acute hepatitis B (AHB) for 1,197 (27.8%), acute hepatitis C (AHC) for 359 (8.3%), and non-A, non-B and non-C (non-ABC) for 1,163 (27.0%). Between 1980 and 1995, the proportions of AHA, AHB, AHC and non-ABC were approximately 40, 25, 10 and 25%; between 1996 and 2003, they were approximately 30, 30, 10 and 30%, and this shifted to approximately 10, 40, 10 and 40% in the last 5 years. The number of AHB caused by genotype A, which is not indigenous to Japan, was 6.0% between 1991 and 1996 but has been markedly increasing since 2000, to reach 52% in 2008. Autochthonous acute hepatitis E (AHE) accounted for 10–15% of non-ABC hepatitis after 2002. The etiology of AVH in Japan has been drastically changing. A marked increase of AHB genotype A and constant occurrence of autochthonous AHE require attention, and necessary measures should be taken.


Gut | 2012

Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B

Yoko Tamada; Hiroshi Yatsuhashi; Naohiko Masaki; Makoto Nakamuta; Eiji Mita; Tatsuji Komatsu; Yukio Watanabe; Toyokichi Muro; Masaaki Shimada; Taizo Hijioka; Takeaki Satoh; Yutaka Mano; Toshiki Komeda; Masahiko Takahashi; Hiroshi Kohno; Hajime Ota; Shigeki Hayashi; Yuzo Miyakawa; Seigo Abiru; Hiromi Ishibashi

Objective To examine recent trends of acute infection with hepatitis B virus (HBV) in Japan by nationwide surveillance and phylogenetic analyses. Methods During 1991 through 2009, a sentinel surveillance was conducted in 28 national hospitals in a prospective cohort study. Genotypes of HBV were determined in 547 patients with acute hepatitis B. Nucleotide sequences in the preS1/S2/S gene of genotype A and B isolates were determined for phylogenetic analyses. Results HBV genotype A was detected in 137 (25% (accompanied by genotype G in one)) patients, B in 48 (9%), C in 359 (66%), and other genotypes in the remaining three (0.5%). HBV persisted in five with genotype A including the one accompanied by genotype G; another was co-infected with HIV type 1. The genotype was A in 4.8% of patients during 1991–1996, 29.3% during 1997–2002, and 50.0% during 2003–2008 in the capital region, as against 6.5%, 8.5% and 33.1%, respectively, in other regions. Of the 114 genotype A isolates, 13 (11.4%) were subgenotype A1, and 101 (88.6%) were A2, whereas of the 43 genotype B isolates, 10 (23.3%) were subgenotype B1, 28 (65.1%) were B2, two (4.7%) were B3, and three (7.0%) were B4. Sequences of 65 (64%) isolates of A2 were identical, as were three (23%) of A1, and five (18%) of B2, but none of the B1, B3 and B4 isolates shared a sequence. Conclusions Acute infection with HBV of genotype A, subgenotype A2 in particular, appear to be increasing, mainly through sexual contact, and spreading from the capital region to other regions in Japan nationwide. Infection persisted in 4% of the patients with genotype A, and HBV strains with an identical sequence prevailed in subgenotype A2 infections. This study indicates the need for universal vaccination of young people to prevent increases in HBV infection in Japan.


FEBS Letters | 2005

Peroxynitrite‐mediated matrix metalloproteinase‐2 activation in human hepatic stellate cells

Kiyoshi Migita; Yumi Maeda; Seigo Abiru; Atsumasa Komori; Terufumi Yokoyama; Yasushi Takii; Minoru Nakamura; Hiroshi Yatsuhashi; Katsumi Eguchi; Hiromi Ishibashi

To investigate whether hepatic stellate cells (HSCs) alter their expression of MMPs after exposure to nitrogen oxide intermediate (NOI), a human hepatic stellate cell line, LI90 cells, was stimulated with an NO donor, SNAP, or a peroxynitrite donor, SIN‐1, and the culture supernatants were analyzed by gelatin zymography or anti‐MMPs immunoblot. Although SIN‐1 did not enhance the secretions of MMP‐1 and 13, SIN‐1 induced the NF‐κB activation, MT1‐MMP expression and the secretion of activated MMP‐2 in LI90 cells. These results suggest that peroxynitrite may contribute to the remodeling of the extracellular matrix in liver by activating pro‐MMP‐2.


Liver International | 2012

Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study)

Kiyoshi Migita; Yukio Watanabe; Yuka Jiuchi; Yoko Nakamura; Akira Saito; Michiyasu Yagura; Hajime Ohta; Masaaki Shimada; Eiji Mita; Taizo Hijioka; Haruhiro Yamashita; Eiichi Takezaki; Toyokichi Muro; Hironori Sakai; Makoto Nakamuta; Seigo Abiru; Atsumasa Komori; Masahiro Ito; Hiroshi Yatsuhashi; Minoru Nakamura; Hiromi Ishibashi

Although the outcome of autoimmune hepatitis (AIH) is generally good, the natural course and likelihood of progression to cirrhosis or hepatocellular carcinoma (HCC) remain undefined, and may vary by region and population structure. Our aims were to evaluate risk factors that contribute to poor outcome and particularly development of HCC in a prospective multicentric cohort study of AIH.


FEBS Letters | 2004

Lipopolysaccharide signaling induces serum amyloid A (SAA) synthesis in human hepatocytes in vitro

Kiyoshi Migita; Seigo Abiru; Minoru Nakamura; Atsumasa Komori; Yuki Yoshida; Terufumi Yokoyama; Manabu Daikoku; Toshihito Ueki; Yasushi Takii; Koji Yano; Hiroshi Yastuhashi; Katsumi Eguchi; Hiromi Ishibashi

To investigate the role of lipopolysaccharide (LPS) in hepatocyte activation, we examined the expression of Toll‐like receptor 4 (TLR4), the putative receptor for LPS in human hepatocytes. TLR4 mRNA and protein expression was confirmed in human hepatocytes. Stimulation of human hepatocytes with LPS results in rapid degradation of IkappaB‐α and mitogen activated protein kinase activation. Human hepatocytes stimulated by LPS produced serum amyloid A protein. Our data suggest that human hepatocytes utilize components of TLR4 signal transduction pathways in response to LPS and these direct LPS‐mediated effects on hepatocytes may contribute to liver inflammation and injury.

Collaboration


Dive into the Seigo Abiru's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kiyoshi Migita

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge